| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 293.7% | Wedbush | $17 → $5 | Maintains | Outperform |
| 09/06/2023 | 2025.98% | Truist Securities | → $27 | Reiterates | Buy → Buy |
| 08/11/2023 | 1947.24% | HC Wainwright & Co. | $38 → $26 | Maintains | Buy |
| 08/10/2023 | 687.4% | BTIG | $20 → $10 | Maintains | Buy |
| 08/10/2023 | 1238.58% | Wedbush | → $17 | Reiterates | Outperform → Outperform |
| 06/27/2023 | 1474.8% | Guggenheim | → $20 | Downgrades | Buy → Neutral |
| 06/27/2023 | 2892.13% | HC Wainwright & Co. | → $38 | Reiterates | Buy → Buy |
| 06/27/2023 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 06/01/2023 | 372.44% | JP Morgan | $20 → $6 | Downgrades | Overweight → Neutral |
| 05/15/2023 | 1396.06% | JMP Securities | → $19 | Reiterates | Market Outperform → Market Outperform |
| 05/10/2023 | 2262.2% | Wedbush | → $30 | Reiterates | → Outperform |
| 05/10/2023 | 2892.13% | HC Wainwright & Co. | → $38 | Maintains | Buy |
| 03/16/2023 | 2262.2% | Wedbush | → $30 | Reiterates | → Outperform |
| 03/16/2023 | 2892.13% | HC Wainwright & Co. | → $38 | Reiterates | → Buy |
| 12/12/2022 | 2892.13% | HC Wainwright & Co. | $34 → $38 | Maintains | Buy |
| 09/21/2022 | 1711.02% | JP Morgan | → $23 | Initiates Coverage On | → Overweight |
| 03/31/2022 | 2104.72% | SMBC Nikko | → $28 | Initiates Coverage On | → Outperform |
| 03/17/2022 | 1553.54% | JMP Securities | $30 → $21 | Maintains | Market Outperform |
| 03/08/2022 | 2262.2% | Truist Securities | → $30 | Initiates Coverage On | → Buy |
| 03/04/2022 | 2025.98% | Jefferies | → $27 | Initiates Coverage On | → Buy |
| 12/06/2021 | 2419.69% | Guggenheim | $22 → $32 | Maintains | Buy |
| 05/18/2021 | 2577.17% | BTIG | → $34 | Initiates Coverage On | → Buy |
| 04/29/2021 | 2498.43% | JonesTrading | → $33 | Initiates Coverage On | → Buy |
| 04/23/2021 | 2025.98% | HC Wainwright & Co. | → $27 | Initiates Coverage On | → Buy |
| 04/14/2021 | 2104.72% | Canaccord Genuity | → $28 | Initiates Coverage On | → Buy |
| 04/08/2021 | 1632.28% | Guggenheim | → $22 | Initiates Coverage On | → Buy |
| 11/04/2020 | 2262.2% | B. Riley Securities | → $30 | Initiates Coverage On | → Buy |
| 10/16/2020 | 1868.5% | Wedbush | → $25 | Initiates Coverage On | → Outperform |
What is the target price for Adicet Bio (ACET)?
The latest price target for Adicet Bio (NASDAQ: ACET) was reported by Wedbush on November 9, 2023. The analyst firm set a price target for $5.00 expecting ACET to rise to within 12 months (a possible 293.70% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adicet Bio (ACET)?
The latest analyst rating for Adicet Bio (NASDAQ: ACET) was provided by Wedbush, and Adicet Bio maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Adicet Bio (ACET)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adicet Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adicet Bio was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Adicet Bio (ACET) correct?
While ratings are subjective and will change, the latest Adicet Bio (ACET) rating was a maintained with a price target of $17.00 to $5.00. The current price Adicet Bio (ACET) is trading at is $1.27, which is out of the analyst's predicted range.